Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Clinical Intervention Awards, 2010
    Maintenance of Continuous Plasma Levodopa Levels through Continuous Subcutaneous Carbidopa Administration

    Objective/Rationale
    In Parkinson’s disease (PD) therapeutics, carbidopa is used together with levodopa to prevent its breakdown. This investigation will determine whether subcutaneous carbidopa...

  • Rapid Response Innovation Awards, 2010
    Biomarkers and Immunotherapy for Parkinson's Disease

    Objective/Rationale:
    We theorize that the interplay between the immune system and the brain plays a substantive role in the progression of Parkinson’s disease. Moreover, we posit that the immune system...

  • Rapid Response Innovation Awards, 2010
    Mechanism and Modulation of Alpha-Synuclein Expression

    Promising Outcomes of Original Grant:
    In the initial grant, we tested the hypothesis that GATA-2 is a direct regulator of alpha-synuclein expression in dopaminergic neurons and therefore represents a...

  • Rapid Response Innovation Awards, 2010
    In Vivo Assessment of Alpha-Synuclein Secretion

    Objective/Rationale
    Recent data from our lab (Emmanouilidou et al, 2010) suggest that cell-produced physiologically secreted alpha-synuclein can cause the death of neuronal recipient cells. Although...

  • MJFF Research Grant, 2010
    Regulated rAAV-GDNF to treat Parkinson's disease: Translational research plan

    Objective/Rationale
    We are attempting to perfect gene therapy using glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease. One part of developing this gene therapy is...

  • Neurotrophic Factor Therapies for Parkinson's Disease, 2010
    CDNF (Cerebral Dopamine Neurotrophic Factor) for Therapy of Parkinson's Disease

    Objective/Rationale:
    CDNF protein is expressed in human brain, acts differently from known neurotrophic factors and can protect and repair dopamine neurons in two pre-clinical models of Parkinson’s...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.